Clinical relevance of KRAS mutations in codon 13: Where are we?

Cancer Letters

Volumn 343, Issue 1, 2014, Pages 1-5

  Er, Tze Kiong ^a   Chen, Chih Chieh ^a,b,c   Bujanda, Luis ^d   Herreros Villanueva, Marta ^d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e Mayo Clinic   (United States)

Author keywords

Anti EGFR therapies; Codon 12 and 13; Colorectal cancer; KRAS

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER INHIBITION; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); CODON; COLORECTAL CANCER; DRUG EFFICACY; GENE FUNCTION; GENE MUTATION; HUMAN; METASTASIS POTENTIAL; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; SHORT SURVEY; TREATMENT RESPONSE;

EID: 84890857294     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.012     Document Type: Review

References (49)

1. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 2012 Jul-Aug, 62(4):220-241.
2. US Food and Drug Administration, FDA approves Erbitux for colorectal cancer, 2004 http://www.fda.gov.
3. US Food and Drug Administration, FDA approves Vectibix (panitumumab) to treat metastatic colorectal carcinoma, http://www.fad.gov.
4. Allegra C.J., et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27(12):2091-2096.
5. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66(8):3992-3995.
6. Lievre A., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26(3):374-379.
7. Karapetis C.S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359(17):1757-1765.
8. Herreros-Villanueva M., et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol. Biol. Rep. 2011, 38(2):1315-1320.
9. Richman S.D., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 2009, 27(35):5931-5937.
10. Di Fiore F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 2007, 96(8):1166-1169.
11. Edkins S., et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol. Ther. 2006, 5(8):928-932.
12. Loupakis F., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 2009, 101(4):715-721.
13. Herreros-Villanueva M., et al. PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. Mol. Biol. Rep. 2011, 38(2):1347-1351.
14. Guerrero S., et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000, 60(23):6750-6756.
15. Guerrero S., et al. Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J. 2002, 16(12):1642-1644.
16. Smith G., et al. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br. J. Cancer 2010, 102(4):693-703.
17. Cespedes M.V., et al. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 2006, 27(11):2190-2200.
18. Seeburg P.H., et al. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984, 312(5989):71-75.
19. Andreyev H.J., et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl. Cancer Inst. 1998, 90(9):675-684.
20. Malumbres M., Barbacid M. RAS oncogenes: the first 30years. Nat. Rev. Cancer 2003, 3(6):459-465.
21. Bos J.L., et al. Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 1985, 315(6022):726-730.
22. Ward R.L., et al. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 1997, 79(6):1106-1113.
23. Chen C.C., et al. Computational analysis of KRAS mutations: implications for different effects on the KRAS p. G12D and p.G13D mutations. PLoS One 2013, 8(2):e55793.
24. Morelli M.P., Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J. Clin. Oncol. 2012, 30(29):3565-3567.
25. Locker G.Y., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24(33):5313-5327.
26. Anwar S., et al. Systematic review of genetic influences on the prognosis of colorectal cancer. Br. J. Surg. 2004, 91(10):1275-1291.
27. McLeod H.L., Church R.D. Molecular predictors of prognosis and response to therapy in colorectal cancer. Cancer Chemother. Biol. Response Modif. 2003, 21:791-801.
28. Westra J.L., et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol. 2005, 23(24):5635-5643.
29. Andreyev H.J., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 2001, 85(5):692-696.
30. Russo A., et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann. Oncol. 2005, 16(Suppl. 4):iv44-iv49.
31. Pajkos G., et al. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res. 2000, 20(3A):1695-1701.
32. Samowitz W.S., et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2000, 9(11):1193-1197.
33. Bazan V., et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann. Oncol. 2002, 13(9):1438-1446.
34. Modest D.P., et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 2011, 22(9):913-918.
35. Imamura Y., et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 2012, 18(17):4753-4763.
36. Smith J.C., et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. Eur. J. Cancer 2013, 49(10):2424-2432.
37. Reinacher-Schick A., et al. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer 2012, 12:349.
38. De Roock W., et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304(16):1812-1820.
39. Tejpar S., et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 2012, 30(29):3570-3577.
40. Messner I., et al. KRAS p. G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J. Cancer Res. Clin. Oncol. 2013, 139(2):201-209.
41. Benvenuti S., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67(6):2643-2648.
42. De Roock W., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19(3):508-515.
43. Bando H., et al. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p. G13D mutation treated with cetuximab + irinotecan. Jpn. J. Clin. Oncol. 2012, 42(12):1146-1151.
44. Mao C., et al. KRAS p. G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 2013, 119(4):714-721.
45. Gajate P., et al. Influence of KRAS p. G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 2012, 11(4):291-296.
46. Peeters M., et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 2013, 31(6):759-765.
47. Montagut C., et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18(2):221-223.
48. O'Reilly K.E., et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66(3):1500-1508.
49. Woo J., et al. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 2013, 119(11):1941-1950.